A genomewide screen for suppressors of Alu-mediated rearrangements reveals a role for PIF1

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Chisholm, Karen M ^a,b,d   Aubert, Sarah D ^c   Freese, Krister P ^b   Zakian, Virginia A ^c   King, Mary Claire ^a,b   Welcsh, Piri L ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c PRINCETON UNIVERSITY   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALU 2 GENE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CODON; CONTROLLED STUDY; ELG1 GENE; FANCM GENE; GENE IDENTIFICATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC RECOMBINATION; GENETIC STABILITY; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HOMOLOGOUS RECOMBINATION; MITOCHONDRION; NONHUMAN; NUCLEOTIDE SEQUENCE; OMA1 GENE; OTC GENE; PIF1 GENE; PRDX1 GENE; PRDX2 GENE; PRDX3 GENE; PRDX4 GENE; RRM3 GENE; SCHIZOSACCHAROMYCES POMBE; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; SUPPRESSOR GENE; TSA GENE; BREAST TUMOR; DNA SEQUENCE; FAMILY; FEMALE; FUNGAL GENOME; GENETIC PREDISPOSITION; GENETICS; HUMAN; PHYSIOLOGY; TUMOR GENE; YEAST;

HELICASE; PFH1 PROTEIN, S POMBE; PIF1 PROTEIN, HUMAN; SCHIZOSACCHAROMYCES POMBE PROTEIN;

BREAST NEOPLASMS; DNA HELICASES; FAMILY; FEMALE; GENE REARRANGEMENT; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME, FUNGAL; HUMANS; SCHIZOSACCHAROMYCES POMBE PROTEINS; SEQUENCE ANALYSIS, DNA; YEASTS;

EID: 84856801304     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030748     Document Type: Article

References (65)

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921.
2. Deininger PL, Batzer MA, (1999) Alu repeats and human disease. Mol Genet Metab 67: 183-193.
3. Smith TM, Lee MK, Szabo CI, Jerome N, McEuen M, et al. (1996) Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res 6: 1029-1049.
4. Sluiter MD, van Rensburg EJ, (2010) Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat Online First™.
5. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, et al. (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Jama 295: 1379-1388.
6. Futreal PA, Soderkvist P, Marks JR, Iglehart JD, Cochran C, et al. (1992) Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res 52: 2624-2627.
7. Borg A, Zhang QX, Johannsson O, Olsson H, (1994) High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas. J Natl Cancer Inst 86: 792-794.
8. Cropp CS, Nevanlinna HA, Pyrhonen S, Stenman UH, Salmikangas P, et al. (1994) Evidence for involvement of BRCA1 in sporadic breast carcinomas. Cancer Res 54: 2548-2551.
9. Devilee P, Schuuring E, van de Vijver MJ, Cornelisse CJ, (1994) Recent developments in the molecular genetic understanding of breast cancer. Crit Rev Oncog 5: 247-270.
10. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, et al. (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120-122.
11. Rio PG, Pernin D, Bay JO, Albuisson E, Kwiatkowski F, et al. (1998) Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma. Int J Oncol 13: 849-853.
12. Tong D, Kucera E, Schuster E, Schmutzler RK, Swoboda H, et al. (2000) Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors. Int J Cancer 88: 319-322.
13. Mueller CR, Roskelley CD, (2003) Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res 5: 45-52.
14. Russell PA, Pharoah PD, De Foy K, Ramus SJ, Symmonds I, et al. (2000) Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. Int J Cancer 87: 317-321.
15. Beckmann MW, Picard F, An HX, van Roeyen CR, Dominik SI, et al. (1996) Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer 73: 1220-1226.
16. Ji HP, King MC, (2001) A functional assay for mutations in tumor suppressor genes caused by mismatch repair deficiency. Hum Mol Genet 10: 2737-2743.
17. Kolodner R, (1996) Biochemistry and genetics of eukaryotic mismatch repair. Genes Dev 10: 1433-1442.
18. Modrich P, Lahue R, (1996) Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem 65: 101-133.
19. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, et al. (1999) Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285: 901-906.
20. Schiestl RH, Gietz RD, (1989) High efficiency transformation of intact yeast cells using single stranded nucleic acids as a carrier. Curr Genet 16: 339-346.
21. Woods RA, Gietz RD, (2001) High-efficiency transformation of plasmid DNA into yeast. Methods Mol Biol 177: 85-97.
22. Gietz RD, Woods RA, (2002) Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. Methods Enzymol 350: 87-96.
23. Lea DAaC, C.A. (1949) The distribution of the numbers of mutants in bacterial populations. J Genet 49: 264-285.
24. Marsischky GT, Filosi N, Kane MF, Kolodner R, (1996) Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes Dev 10: 407-420.
25. Huang J, Papadopoulos N, McKinley AJ, Farrington SM, Curtis LJ, et al. (1996) APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci U S A 93: 9049-9054.
26. Moreno S, Klar A, Nurse P, (1991) Molecular Genetic-Analysis of Fission Yeast Schizosaccharomyces-Pombe. Methods in Enzymology 194: 795-823.
27. Kanter-Smoler G, Dahlkvist A, Sunnerhagen P, (1994) Improved method for rapid transformation of intact Schizosaccharomyces pombe cells. Biotechniques 16: 798-800.
28. Werler PJH, Hartsuiker E, Carr AM, (2003) A simple Cre-loxP method for chromosomal N-terminal tagging of essential and non-essential Schizosaccharomyces pombe genes. Gene 304: 133-141.
29. Zhou JQ, Qi HY, Schulz VP, Mateyak MK, Monson EK, et al. (2002) Schizosaccharomyces pombe pfh1(+) encodes an essential 5′ to 3′ DNA helicase that is a member of the PIF1 subfamily of DNA helicases. Molecular Biology of the Cell 13: 2180-2191.
30. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117-1130.
31. Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A, et al. (2006) Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci U S A 103: 3770-3774.
32. Rebbeck TR, (2002) Inherited predisposition and breast cancer: modifiers of BRCA1/2-associated breast cancer risk. Environ Mol Mutagen 39: 228-234.
33. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, et al. (2002) A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 86: 76-83.
34. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, et al. (2008) Variation of breast cancer risk among BRCA1/2 carriers. Jama 299: 194-201.
35. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, et al. (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98: 1457-1466.
36. Lloyd J, Flanagan AM, (2000) Mammary and extramammary Paget's disease. J Clin Pathol 53: 742-749.
37. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, et al. (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20: 1480-1490.
38. Zhang DH, Zhou B, Huang Y, Xu LX, Zhou JQ, (2006) The human Pif1 helicase, a potential Escherichia coli RecD homologue, inhibits telomerase activity. Nucleic Acids Res 34: 1393-1404.
39. Pinter SF, Aubert SD, Zakian VA, (2008) The Schizosaccharomyces pombe Pfh1p DNA helicase is essential for the maintenance of nuclear and mitochondrial DNA. Mol Cell Biol 28: 6594-6608.
40. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT, (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9: 444-450.
41. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, et al. (1999) Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21: 236-240.
42. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, et al. (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92: 564-569.
43. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW, (2000) Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21: 1761-1765.
44. Catteau A, Harris WH, Xu CF, Solomon E, (1999) Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18: 1957-1965.
45. Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE, (2002) Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 94: 61-67.
46. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, et al. (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60: 5329-5333.
47. Staff S, Isola J, Tanner M, (2003) Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res 63: 4978-4983.
48. Huang ME, Rio AG, Nicolas A, Kolodner RD, (2003) A genomewide screen in Saccharomyces cerevisiae for genes that suppress the accumulation of mutations. Proc Natl Acad Sci U S A 100: 11529-11534.
49. Smith S, Hwang JY, Banerjee S, Majeed A, Gupta A, et al. (2004) Mutator genes for suppression of gross chromosomal rearrangements identified by a genome-wide screening in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 101: 9039-9044.
50. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, et al. (2003) Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424: 561-565.
51. Jauniaux JC, Urrestarazu LA, Wiame JM, (1978) Arginine metabolism in Saccharomyces cerevisiae: subcellular localization of the enzymes. J Bacteriol 133: 1096-1107.
52. Miller BJ, Wang D, Krahe R, Wright FA, (2003) Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am J Hum Genet 73: 748-767.
53. Bochman ML, Sabouri N, Zakian VA, (2010) Unwinding the functions of the Pif1 family helicases. DNA Repair (Amst) 9: 237-249.
54. Snow BE, Mateyak M, Paderova J, Wakeham A, Iorio C, et al. (2007) Murine Pif1 interacts with telomerase and is dispensable for telomere function in vivo. Mol Cell Biol 27: 1017-1026.
55. Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO, Borg A, et al. (2003) Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res 63: 8861-8868.
56. Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, et al. (2004) Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 64: 8541-8549.
57. Naylor TL, Greshock J, Wang Y, Colligon T, Yu QC, et al. (2005) High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res 7: R1186-1198.
58. Nessling M, Richter K, Schwaenen C, Roerig P, Wrobel G, et al. (2005) Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res 65: 439-447.
59. Pierga JY, Reis-Filho JS, Cleator SJ, Dexter T, Mackay A, et al. (2007) Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer 96: 341-351.
60. Evers B, Jonkers J, (2006) Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 25: 5885-5897.
61. Ludwig T, Fisher P, Ganesan S, Efstratiadis A, (2001) Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev 15: 1188-1193.
62. Xu X, Wagner KU, Larson D, Weaver Z, Li C, et al. (1999) Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22: 37-43.
63. Clark-Knowles KV, Garson K, Jonkers J, Vanderhyden BC, (2007) Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res 313: 133-145.
64. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, et al. (2007) Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A 104: 12111-12116.
65. Hall MC, Matson SW, (1999) Helicase motifs: the engine that powers DNA unwinding. Mol Microbiol 34: 867-877.